JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.45 1.66

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.38

Max

2.51

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -38M
Müük	1.6M 11M
Kasumimarginaal	-333.127
Töötajad	144
EBITDA	-1.8M -35M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+316.33% upside

Turustatistika
By TradingEconomics
Turukapital	73M 568M
Eelmine avamishind	0.79
Eelmine sulgemishind	2.45

Uudiste sentiment

By Acuity

62%

38%

314 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. okt 2025, 17:40 UTC

Omandamised, ülevõtmised, äriostud

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31. okt 2025, 23:09 UTC

Tulu

Review & Preview: October Surprise -- Barrons.com

31. okt 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31. okt 2025, 21:25 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31. okt 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31. okt 2025, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. okt 2025, 20:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

31. okt 2025, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31. okt 2025, 20:22 UTC

Tulu

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31. okt 2025, 20:02 UTC

Tulu

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31. okt 2025, 19:55 UTC

Market Talk

Crude Futures Fall for Third Straight Month -- Market Talk

31. okt 2025, 19:54 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31. okt 2025, 19:54 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31. okt 2025, 19:26 UTC

Market Talk

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31. okt 2025, 18:30 UTC

Tulu

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31. okt 2025, 18:23 UTC

Market Talk

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31. okt 2025, 18:09 UTC

Tulu

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31. okt 2025, 18:08 UTC

Tulu

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31. okt 2025, 17:36 UTC

Market Talk

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31. okt 2025, 17:31 UTC

Market Talk

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31. okt 2025, 17:16 UTC

Omandamised, ülevõtmised, äriostud

Orange: Acquisition Likely Completed in First Half Next Year

31. okt 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Orange: Agreement Set to Be Signed By Year-Out

31. okt 2025, 17:14 UTC

Omandamised, ülevõtmised, äriostud

Orange: Acquisition Will Strengthen Position in Spain

31. okt 2025, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31. okt 2025, 17:12 UTC

Omandamised, ülevõtmised, äriostud

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

316.33% tõus

12 kuu keskmine prognoos

Keskmine 10.2 USD 316.33%

Kõrge 15 USD

Madal 8 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

314 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.